Ubs Group Ag Finch Therapeutics Group, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $0.56 $54 - $89	-160 Reduced 71.75%	63 $0
Q3 2022 Nov 10, 2022	SELL	$1.75 - $51.3 $5,874 - $172,214	-3,357 Reduced 93.77%	223 $0
Q2 2022 Aug 10, 2022	BUY	$1.91 - $5.11 $4,538 - $12,141	2,376 Added 197.34%	3,580 $11,000
Q1 2022 May 16, 2022	SELL	$5.02 - $10.47 $20,009 - $41,733	-3,986 Reduced 76.8%	1,204 $6,000
Q4 2021 Feb 14, 2022	BUY	$8.95 - $16.88 $32,211 - $60,751	3,599 Added 226.21%	5,190 $52,000
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $10,894 - $14,957	893 Added 127.94%	1,591 $21,000
Q2 2021 Aug 13, 2021	BUY	$12.03 - $17.51 $8,396 - $12,221	698 New	698 $10,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $575M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.